-
1.发明公开公开(公告)号：US20240224963A9
公开(公告)日：2024-07-11
申请号：US18270023
申请日：2022-01-13
Applicant: SHANGHAI ACEMAB CORPORATION LTD
Inventor： Seehong WONG , Jianliang LI
IPC: A01K67/0278 , C07K16/46 , C12N9/22 , C12N15/85 , C12N15/90
CPC classification number: A01K67/0278 , C07K16/464 , C12N9/22 , C12N15/8509 , C12N15/907 , A01K2207/15 , A01K2217/072 , A01K2227/105 , A01K2267/01 , C07K2317/14 , C07K2317/24 , C12N2015/8518 , C12N2800/107 , C12N2800/90
Abstract: Disclosed are a non-human mammalian cell, a recombinant genome thereof, and a method for producing same. The variable region genes of the endogenous immunoglobulin in the genome are partially or entirely replaced with variable region genes of human immunoglobulin, a part or all of the pseudogenes and/or open reading frames of the variable region genes of human immunoglobulin, including coding and non-coding sequences for human heavy chain functional VH, DH, JH, or coding and non-coding sequences for human light chain functional VL, JL, are knocked out. A non-human mammalian cell of the present invention that contains human immunoglobulin domains can be used to produce a transgenic animal that is capable of producing antibodies with fully human variable domain(s), whereby fully human antibodies featuring a higher affinity can be screened efficiently at a lower cost within a shorter period.
-
公开(公告)号：US20240076338A1
公开(公告)日：2024-03-07
申请号：US18501884
申请日：2023-11-03
Applicant: DEKA BIOSCIENCES, INC.
Inventor： John MUMM
CPC classification number: C07K14/5428 , A61P35/00 , A61P37/06 , C07K14/5406 , C07K14/55 , C07K16/10 , C07K16/1045 , C07K16/2803 , C07K16/2863 , C07K16/2896 , C07K16/32 , C07K16/464 , A61K2039/505 , C07K2317/53 , C07K2317/565 , C07K2317/92
Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
-
公开(公告)号：US20240067688A1
公开(公告)日：2024-02-29
申请号：US18501850
申请日：2023-11-03
Applicant: DEKA BIOSCIENCES, INC.
Inventor： John MUMM
CPC classification number: C07K14/5428 , A61P35/00 , A61P37/06 , C07K14/5406 , C07K14/55 , C07K16/10 , C07K16/1045 , C07K16/2803 , C07K16/2863 , C07K16/2896 , C07K16/32 , C07K16/464 , A61K2039/505 , C07K2317/53 , C07K2317/565 , C07K2317/92
Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
-
公开(公告)号：US20240059749A1
公开(公告)日：2024-02-22
申请号：US18501741
申请日：2023-11-03
Applicant: DEKA BIOSCIENCES, INC.
Inventor： John MUMM
CPC classification number: C07K14/5428 , A61P35/00 , A61P37/06 , C07K14/5406 , C07K14/55 , C07K16/10 , C07K16/1045 , C07K16/2803 , C07K16/2863 , C07K16/2896 , C07K16/32 , C07K16/464 , A61K2039/505 , C07K2317/53 , C07K2317/565 , C07K2317/92
Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
-
公开(公告)号：US11680110B2
公开(公告)日：2023-06-20
申请号：US16633423
申请日：2018-07-27
Applicant: Hoffmann-La Roche Inc.
Inventor： Johannes Auer , Guy Georges , Stefan Klostermann , Wolfgang Schaefer
CPC classification number: C07K16/464 , C07K16/244 , C07K16/2866 , C07K2317/24 , C07K2317/565
Abstract: Herein is reported a method for the humanization of non-human antibodies using a structure-based scoring matrix. With the scoring matrix it is possible to determine (the requirement for and) the suitability of specific (back)mutations of amino acid residues at defined positions of a selected human germline sequence. The scoring matrix takes into account the topology, the three-dimensional structure and the interactions of the respective residue and change. Thereby the influence on antigen binding of a specific amino acid residue change can be determined.
-
公开(公告)号：US20190241654A1
公开(公告)日：2019-08-08
申请号：US16315141
申请日：2017-07-05
Applicant: CELGENE CORPORATION
Inventor： Jeffrey C. JOHNSON , Lawrence DEARTH , Haralambos HADJIVASSILIOU , Jeonghoon SUN , Kandasamy HARIHARAN
IPC: C07K16/28
CPC classification number: C07K16/2803 , C07K16/00 , C07K16/461 , C07K16/464 , C07K16/465 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are antibodies and antigen-binding fragments thereof with low or no immunogenicity in humans and optionally with desirable manufacturing properties. Also provided are compositions comprising such antibodies or antigen-binding fragments, methods of using such antibodies, and methods for making such antibodies.
-
公开(公告)号：US09994645B2
公开(公告)日：2018-06-12
申请号：US15193432
申请日：2016-06-27
Applicant: ESBATech—a Novartis Company LLC
Inventor： Dominik Escher
CPC classification number: C07K16/464 , C07H21/00 , C07K16/00 , C07K16/18 , C07K16/241 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/92 , C07K2317/94
Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
-
公开(公告)号：US20170247473A1
公开(公告)日：2017-08-31
申请号：US15593721
申请日：2017-05-12
Applicant: BioAtla, LLC
Inventor： Jay M. Short
CPC classification number: C07K16/461 , C07K16/248 , C07K16/464 , C07K2317/14 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/92
Abstract: The disclosure provides a method for generation of humanized full length antibodies in mammalian cells. A library of humanized variants is provided with high, validated human framework diversity without requiring back-mutations to retain original affinity. Synthetic CDR encoding fragment libraries derived from a template antibody are ligated to human framework region encoding fragments from a human framework pool limited only to germline sequences from a functionally expressed antibodies. The vector comprises a nucleic acid sequence encoding HC framework region 4. No CDR grafting or phage display is required.
-
公开(公告)号：US09617345B2
公开(公告)日：2017-04-11
申请号：US14716377
申请日：2015-05-19
Applicant: SANOFI
Inventor： Pierre-Francois Berne , Francis Blanche , Hervé Bouchard , Béatrice Cameron , Tarik Dabdoubi , Stéphanie Decary , Paul Ferrari , Alexey Rak
IPC: C07K16/30 , A61K47/48 , A61K31/537 , C07K16/28 , C07K16/46 , G01N33/574
CPC classification number: C07K16/3007 , A61K31/537 , A61K47/6803 , A61K47/6849 , A61K47/6853 , C07K16/2896 , C07K16/464 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/77 , C07K2317/92 , G01N33/57473 , G01N2333/70503
Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
-
公开(公告)号：US09540451B2
公开(公告)日：2017-01-10
申请号：US13860484
申请日：2013-04-10
Applicant: Xencor, Inc.
Inventor： John R. Desjarlais , Seung Y. Chu , Holly M. Horton , Matthew J. Bernett
CPC classification number: C07K16/4291 , A61K2039/505 , A61P37/08 , C07K16/464 , C07K2317/24 , C07K2317/52 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
Abstract translation: 本发明涉及以高亲和力结合IgE和FcγRIIb的免疫球蛋白，所述组合物能够抑制表达膜锚定的IgE的细胞。 这样的组合物可用于治疗IgE介导的病症，包括过敏和哮喘。
